Medical Education Library

Advancements in the Delivery of Biologics for the Treatment of Diabetes

Funding for this newsletter series was provided by AstraZeneca

 

Diabetes medication administration often forces patients into uncomfortable situations. Those with complicated treatment or with a fear of needles might hesitate to adhere to their suggested regimen, placing themselves at risk. Over the years, several mechanisms have evolved to help make insulin delivery, and so, betting patient adherence.

This fifth eNewsletter in the series, entitled Advancements in the Delivery of Biologics for the Treatment of Diabetes was written by James Ruggles, PhD, and James Meehan, MSc. It covers the history of insulin delivery methods starting from 1922 and through present day.

Click here to read the supplement

About the Authors:

James Ruggles, PhD
AstraZeneca
Wilmington, DE, USA

James Meehan, MSc
AstraZeneca
Macclesfield, Cheshire, UK

Recommended Reading

Canagliflozin approved for cardiovascular event risk reduction
MDedge Family Medicine
Sleep: The new frontier in cardiovascular prevention
MDedge Family Medicine
Dulaglutide meets primary endpoint in REWIND
MDedge Family Medicine
DPP-4 drugs for diabetes may protect kidneys too
MDedge Family Medicine
Closed-loop basal insulin delivery improves suboptimal T1DM control
MDedge Family Medicine
Lower glucose targets show improved mortality in cardiac patients
MDedge Family Medicine
DECLARE: Dapagliflozin improves some cardiovascular, renal outcomes
MDedge Family Medicine
Cardiologist: Obesity has basically stopped progress on cardiovascular disease
MDedge Family Medicine
Children with poor cardiorespiratory fitness have a higher risk of type 2 diabetes and cardiovascular disease
MDedge Family Medicine
Empagliflozin reduces left ventricular mass
MDedge Family Medicine